Tag: multiple sclerosis

Biogen advances research to improve outcomes for patients with multiple sclerosis

Through its research initiatives, Biogen aims to identify new ways to manage and monitor multiple sclerosis (MS) disease progression and provide physicians with...

Trial shows unprecedented slowing in progressive multiple sclerosis

A drug slowed brain shrinkage in progressive multiple sclerosis (MS) by nearly half, according to new research led by Cleveland Clinic (Ohio, USA). Very...

Brave Dreams trial finds venous angioplasty “safe, but largely ineffective” for...

Paolo Zamboni, Ferrara, Italy, the proponent of the chronic cerebrospinal venous insufficiency (CCSVI) theory, and his colleagues have reported that the randomised, double-blinded, sham...

AFFINITY Phase 2 MS trial begins

Biogen has announced the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab—a human monoclonal antibody targeting LINGO-1—as an investigational...

People with multiple sclerosis face delays in accessing treatments that could...

Sanofi and its specialty care global business unit, Sanofi Genzyme, has published a report—The Missing Pieces, showing that the vast majority (74%) of UK...

CMHP issues positive opinion for Merck’s Cladrabine tablets for multiple sclerosis

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for approval of Cladribine...

Teva Pharmaceutical launches social media campaign for World MS Day

Teva Pharmaceuticals has announced the launch of its ‘Life Moments with MS’ campaign—a disease awareness initiative, highlighting the challenges faced by multiple sclerosis (MS)...

Tecfidera (dimethyl fumarate) and Tysabri (natalizumab) data demonstrate improved outcomes with...

Biogen has announced new real-world data that show treatment with its multiple sclerosis (MS) therapies, Tecfidera (dimethyl fumarate) and Tysabri (natalizumab), early in the...

FDA approves Ocrevus (ocrelizumab) for relapsing and primary progressive forms of...

Genentech has announced that the US Food and Drug Administration (FDA) has approved Ocrevus (ocrelizumab) as the first and only medicine for both relapsing...

Alkermes begins phase 3 gastrointestinal tolerability study of ALKS 8700 for...

Alkermes has initiated a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate (MMF) prodrug candidate in development for the treatment...

NICE recommends Zinbryta (daclizumab) for relapsing-remitting multiple sclerosis

The National Institute for Health and Care Excellence (NICE) has recommended ZINBRYTA (daclizumab) from Biogen for the treatment of adult patients living with relapsing-remitting...

Long-term outcomes following stem cell transplant for multiple sclerosis published in...

A new study published online by JAMA Neurology examines the long-term outcomes of patients with aggressive forms of multiple sclerosis who failed to respond...

Siemens Healthineers and Biogen to jointly develop new MRI tools for...

Siemens Healthineers and Biogen have announced that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key...

ECTRIMS and EAN join forces to formulate the first European MS...

A late-breaking session at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS; 14–17 September, London, UK) presented the Clinical Guideline on...

Tecfidera (dimethyl fumarate) real-world studies affirm sustained efficacy and demonstrate nine-year...

Biogen has announced new Tecfidera (dimethyl fumarate) data at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)...

Six year Lemtrada data presented at ECTRIMS

Sanofi Genzyme has announced the presentation six-year investigational data from the extension study of Lemtrada (alemtuzumab) in patients with relapsing remitting multiple sclerosis (RRMS)....